First patient study data show that idarucizumab* immediately reverses dabigatran within minutes in patients requiring urgent procedures or with serious bleeding complications1,2 ...

Boehringer Ingelheim Pharmaceuticals Inc. announced that the FDA has granted priority review status for the company’s biologics license application for idarucizumab as a reversal agent for the ...

The approval is based on data from healthy volunteers, as well as results from an interim analysis of the RE-VERSE AD™ clinical study.In the studies, the reversal effects of idarucizumab were evident ...